Can you provide the average price target for NEUROPACE INC stock?
14 analysts have analysed NPCE and the average price target is 20.25 USD. This implies a price increase of 22.82% is expected in the next year compared to the current price of 16.491.
NASDAQ:NPCE • US6412881053
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NEUROPACE INC (NPCE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-16 | UBS | Maintains | Buy -> Buy |
| 2025-12-10 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-05 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-13 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-05-28 | HC Wainwright & Co. | Initiate | Buy |
| 2025-05-14 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-05-14 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-03-05 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-01-30 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-01-21 | UBS | Initiate | Buy |
| 2024-12-17 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-11-13 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-08-14 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-14 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-07-15 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-05-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-03-14 | Wells Fargo | Upgrade | Equal-Weight -> Overweight |
| 2024-03-12 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-03-06 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2024-03-06 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-02-22 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2024-01-30 | Leerink Partners | Initiate | Outperform |
| 2023-12-27 | Lake Street | Reiterate | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 65.421M 43.72% | 79.906M 22.14% | 99.986M 25.13% | 100.89M 0.90% | 125.57M 24.46% | 156.66M 24.76% | 188.53M 20.34% | 217.68M 15.46% | |
| EBITDA YoY % growth | -27.002M 33.36% | -21.464M 20.51% | -16.1M 24.99% | -9.755M 39.41% | -1.74M 82.17% | 1.962M 212.78% | N/A | N/A | |
| EBIT YoY % growth | -27.174M 33.38% | -21.671M 20.25% | -16.338M 24.61% | -16.937M -3.67% | -6.555M 61.30% | 1.503M 122.93% | 20.4M 1,257.29% | 25.5M 25.00% | |
| Operating Margin | -41.54% | -27.12% | -16.34% | -16.79% | -5.22% | 0.96% | 10.82% | 11.71% | |
| EPS YoY % growth | -1.28 33.33% | -0.95 25.78% | -0.66 30.53% | -0.65 1.09% | -0.37 43.49% | -0.07 79.95% | 0.09 224.14% | 0.37 300.00% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.23 -11.71% | -0.22 17.05% | -0.11 -3.33% | -0.09 -12.93% | -0.16 31.88% | -0.15 30.63% | -0.10 13.25% | -0.10 -5.37% | -0.20 -27.66% | -0.17 -15.91% | -0.13 -34.48% | -0.09 3.57% |
| Revenue Q2Q % growth | 22.077M -1.98% | 23.632M 0.48% | 27.061M -1.07% | 28.204M 6.08% | 27.627M 25.14% | 29.514M 24.89% | 33.999M 25.64% | 35.825M 27.02% | 35.21M 27.45% | 38.638M 30.91% | 44.268M 30.20% | 49.144M 37.18% |
| EBITDA Q2Q % growth | -5.097M 0.01% | -4.183M 37.75% | -828.648K 66.07% | 557.736K 136.48% | -1.53M 69.98% | -1.326M 68.30% | -102K 87.69% | 714K 28.02% | -5.375M -251.33% | -4.355M -228.46% | -2.785M -2,630.00% | -1.469M -305.71% |
| EBIT Q2Q % growth | -6.996M -35.93% | -6.238M 8.59% | -2.907M -11.81% | -2.093M -18.47% | -4.508M 35.56% | -4.005M 35.79% | -2.295M 21.05% | -2.122M -1.35% | -5.457M -21.04% | -4.447M -11.04% | -2.876M -25.33% | -1.571M 25.96% |
All data in USD
14 analysts have analysed NPCE and the average price target is 20.25 USD. This implies a price increase of 22.82% is expected in the next year compared to the current price of 16.491.
NEUROPACE INC (NPCE) will report earnings on 2026-05-07.
The consensus EPS estimate for the next earnings of NEUROPACE INC (NPCE) is -0.23 USD and the consensus revenue estimate is 22.08M USD.
The consensus rating for NEUROPACE INC (NPCE) is 84.2857 / 100 . This indicates that analysts generally have a positive outlook on the stock.